{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:45:50Z","timestamp":1789422350807,"version":"build-2803163510"},"reference-count":157,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["CSC202006170047"],"award-info":[{"award-number":["CSC202006170047"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Netherlands Heart Foundation","award":["IN CONTROL, CVON2018-27"],"award-info":[{"award-number":["IN CONTROL, CVON2018-27"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>New drugs targeting bile acid metabolism are currently being evaluated in clinical studies for their potential to treat cholestatic liver diseases, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Changes in bile acid metabolism, however, translate into an alteration of plasma cholesterol and triglyceride concentrations, which may also affect cardiovascular outcomes in such patients. This review attempts to gain insight into this matter and improve our understanding of the interactions between bile acid and lipid metabolism. Bile acid sequestrants (BAS), which bind bile acids in the intestine and promote their faecal excretion, have long been used in the clinic to reduce LDL cholesterol and, thereby, atherosclerotic cardiovascular disease (ASCVD) risk. However, BAS modestly but consistently increase plasma triglycerides, which is considered a causal risk factor for ASCVD. Like BAS, inhibitors of the apical sodium-dependent bile acid transporter (ASBTi\u2019s) reduce intestinal bile acid absorption. ASBTi\u2019s show effects that are quite similar to those obtained with BAS, which is anticipated when considering that accelerated faecal loss of bile acids is compensated by an increased hepatic synthesis of bile acids from cholesterol. Oppositely, treatment with farnesoid X receptor agonists, resulting in inhibition of bile acid synthesis, appears to be associated with increased LDL cholesterol. In conclusion, the increasing efforts to employ drugs that intervene in bile acid metabolism and signalling pathways for the treatment of metabolic diseases such as NAFLD warrants reinforcing interactions between the bile acid and lipid and lipoprotein research fields. This review may be considered as the first step in this process.<\/jats:p>","DOI":"10.3390\/jcm11010004","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T09:50:43Z","timestamp":1640080243000},"page":"4","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles"],"prefix":"10.3390","volume":"11","author":[{"given":"Boyan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert","family":"Kuipers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, The Netherlands"},{"name":"Department of Laboratory Medicine, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-3291","authenticated-orcid":false,"given":"Jan Freark","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, The Netherlands"},{"name":"Department of Laboratory Medicine, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Albert","family":"Kuivenhoven","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"ref_1","first-page":"125","article-title":"Decreased fecal bile acid output in patients with coronary atherosclerosis","volume":"29","author":"Charach","year":"1998","journal-title":"J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Charach, G., Argov, O., Geiger, K., Charach, L., Rogowski, O., and Grosskopf, I. (2018). Diminished bile acids excretion is a risk factor for coronary artery disease: 20-year follow up and long-term outcome. Therap. Adv. Gastroenterol., 11.","DOI":"10.1177\/1756283X17743420"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2019.12.010","article-title":"Reduced bile acid excretion is an independent risk factor for stroke and mortality: A prospective follow-up study","volume":"293","author":"Charach","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"(1984). The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease. JAMA J. Am. Med. Assoc., 251, 351\u2013364.","DOI":"10.1001\/jama.251.3.351"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"(1984). The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The Relationship of Reduction in Incidence of Coronary Heart Disease to Cholesterol Lowering. JAMA J. Am. Med. Assoc., 251, 365\u2013374.","DOI":"10.1001\/jama.251.3.365"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/eurheartj\/ehy068","article-title":"Genetic variants in CYP7A1 and risk of myocardial infarction and symptomatic gallstone disease","volume":"39","author":"Qayyum","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrendo.2014.60","article-title":"Beyond intestinal soap\u2014Bile acids in metabolic control","volume":"10","author":"Kuipers","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2003.11.006","article-title":"Regulation of bile acid synthesis: Pathways, nuclear receptors, and mechanisms","volume":"40","author":"Chiang","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.celrep.2020.108212","article-title":"Genetic and Microbial Associations to Plasma and Fecal Bile Acids in Obesity Relate to Plasma Lipids and Liver Fat Content","volume":"33","author":"Chen","year":"2020","journal-title":"Cell Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.3748\/wjg.v19.i42.7341","article-title":"Physiological and molecular biochemical mechanisms of bile formation","volume":"19","author":"Reshetnyak","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MOL.0000000000000508","article-title":"New insights in the multiple roles of bile acids and their signaling pathways in metabolic control","volume":"29","author":"Bloks","year":"2018","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cphy.c120023","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0168-8278(97)80338-8","article-title":"New insights into cholangiocyte physiology","volume":"27","author":"Strazzabosco","year":"1997","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/cphy.c120027","article-title":"Bile formation and secretion","volume":"3","author":"Boyer","year":"2013","journal-title":"Compr. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/apt.16118","article-title":"Review article: Liver disease in adults with variants in the cholestasis-related genes ABCB11, ABCB4 and ATP8B1","volume":"52","author":"Nayagam","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Williams, K., Segard, A., and Graf, G.A. (2021). Sitosterolemia: Twenty Years of Discovery of the Function of ABCG5ABCG8. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052641"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"954781","DOI":"10.1155\/2014\/954781","article-title":"Molecular mechanisms for biliary phospholipid and drug efflux mediated by ABCB4 and bile salts","volume":"2014","author":"Morita","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cphy.c190007","article-title":"Intestinal Absorption of Bile Acids in Health and Disease","volume":"10","author":"Ticho","year":"2019","journal-title":"Compr. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"G1242","DOI":"10.1152\/ajpgi.2000.279.6.G1242","article-title":"Intestinal absorption and postabsorptive metabolism of linoleic acid in rats with short-term bile duct ligation","volume":"279","author":"Minich","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1388-1981(99)00033-5","article-title":"Bile diversion in rats leads to a decreased plasma concentration of linoleic acid which is not due to decreased net intestinal absorption of dietary linoleic acid","volume":"1438","author":"Minich","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1152\/physrev.00049.2019","article-title":"Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging","volume":"101","author":"Perino","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: Natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bite acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile Acids as Hormones: The FXR-FGF15\/19 Pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.dld.2020.12.065","article-title":"NR1H4 rs35724 G>C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease","volume":"53","author":"Grimaudo","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s42003-018-0015-9","article-title":"A rare missense variant in NR1H4 associates with lower cholesterol levels","volume":"1","author":"Deaton","year":"2018","journal-title":"Commun. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1074\/jbc.M209525200","article-title":"The farnesoid X-receptor is an essential regulator of cholesterol homeostasis","volume":"278","author":"Lambert","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cmet.2009.08.005","article-title":"Bile acids have the gall to function as hormones","volume":"10","author":"Edwards","year":"2009","journal-title":"Cell Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/cvr\/cvz253","article-title":"Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development","volume":"116","author":"Zhou","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_35","first-page":"E136","article-title":"Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA","volume":"264","author":"Neese","year":"1993","journal-title":"Am. J. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2017.11.006","article-title":"Cholesterol Transport Revisited: A New Turbo Mechanism to Drive Cholesterol Excretion","volume":"29","author":"Kuipers","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/10256010903356888","article-title":"Developments in bile acid kinetic measurements using (13)C and (2)H: 10(5) times improved sensitivity during the last 40 years","volume":"45","author":"Stellaard","year":"2009","journal-title":"Isotopes Environ. Health Stud."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/bms.1200141106","article-title":"Simultaneous determination of pool sizes and fractional turnover rates, of deoxycholic acid, cholic acid and chenodeoxycholic acid in man by isotope dilution with 2H and 13C labels and serum sampling","volume":"14","author":"Stellaard","year":"1987","journal-title":"Biomed. Environ. Mass Spectrom."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-3-319-09665-0_8","article-title":"Beyond the genetics of HDL: Why is HDL cholesterol inversely related to cardiovascular disease?","volume":"224","author":"Kuivenhoven","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MOL.0b013e32834477d2","article-title":"Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: Concordance and discordance with cardiovascular disease risk","volume":"22","author":"Nordestgaard","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1194\/jlr.R001610","article-title":"The HDL hypothesis: Does high-density lipoprotein protect from atherosclerosis?","volume":"51","author":"Vergeer","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MOL.0000000000000161","article-title":"HDL re-examined","volume":"26","author":"Hovingh","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MOG.0000000000000057","article-title":"Bile acids and the gut microbiome","volume":"30","author":"Ridlon","year":"2014","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/CIRCRESAHA.115.306807","article-title":"The gut microbiome contributes to a substantial proportion of the variation in blood lipids","volume":"117","author":"Fu","year":"2015","journal-title":"Circ. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1194\/jlr.RA119000243","article-title":"A human-like bile acid pool induced by deletion of hepatic Cyp2c70 modulates effects of FXR activation in mice","volume":"61","author":"Verkade","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"G494","DOI":"10.1152\/ajpgi.00156.2003","article-title":"Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: Studies in the gallstone-susceptible mouse","volume":"285","author":"Wang","year":"2003","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1194\/jlr.RA119000395","article-title":"Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition","volume":"61","author":"Honda","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1194\/jlr.RA119000307","article-title":"Of mice and men: Murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism","volume":"61","author":"Straniero","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jcmgh.2020.12.004","article-title":"Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid","volume":"11","author":"Palmiotti","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.2337\/diabetes.54.12.3554","article-title":"Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: Role of CETP and triglycerides","volume":"54","author":"Perton","year":"2005","journal-title":"Diabetes"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0014-5793(88)80944-X","article-title":"Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man","volume":"239","author":"Axelson","year":"1988","journal-title":"FEBS Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0014-5793(91)80688-Y","article-title":"The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man","volume":"284","author":"Axelson","year":"1991","journal-title":"FEBS Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"E167","DOI":"10.1152\/ajpendo.00416.2016","article-title":"Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated","volume":"313","author":"Straniero","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2005.12.022","article-title":"Protein sensors for membrane sterols","volume":"124","author":"Goldstein","year":"2006","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2165\/00003495-200767100-00001","article-title":"Bile acid sequestrants and the treatment of type 2 diabetes mellitus","volume":"67","author":"Staels","year":"2007","journal-title":"Drugs"},{"key":"ref_58","first-page":"995","article-title":"The effect of colesevelam treatment on bile acid and lipid metabolism and glycemic control in healthy men","volume":"65","year":"2016","journal-title":"Physiol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11739-011-0653-0","article-title":"Use and indications of cholestyramine and bile acid sequestrants","volume":"8","author":"Scaldaferri","year":"2013","journal-title":"Intern. Emerg. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2013.06.014","article-title":"The efficacy of colesevelam HCL in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients","volume":"35","author":"Davidson","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpeds.2009.08.037","article-title":"Colesevelam Hydrochloride: Efficacy and Safety in Pediatric Subjects with Heterozygous Familial Hypercholesterolemia","volume":"156","author":"Stein","year":"2010","journal-title":"J. Pediatr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2016.07.923","article-title":"Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin","volume":"252","author":"Watts","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1463-1326.2009.01159.x","article-title":"Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: A randomized double-blind placebo-controlled study","volume":"12","author":"Kondo","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1479164112461657","article-title":"Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia","volume":"10","author":"Goldberg","year":"2013","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_65","first-page":"348","article-title":"The glucose and lipid effects of colesevelam as monotherapy in drug-na\u00efve type 2 diabetes","volume":"46","author":"Rosenstock","year":"2014","journal-title":"Horm. Metab. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1073\/pnas.84.15.5434","article-title":"Bile acid metabolism in hereditary forms of hypertriglyceridemia: Evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia","volume":"84","author":"Angelin","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0022-2275(20)40684-4","article-title":"Bile acid kinetics in relation to endogenous tryglyceride metabolism in various types of hyperlipoproteinemia","volume":"19","author":"Angelin","year":"1978","journal-title":"J. Lipid Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db11-0030","article-title":"Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity","volume":"60","author":"Prawitt","year":"2011","journal-title":"Diabetes"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1016\/j.febslet.2007.09.064","article-title":"FXR-deficiency confers increased susceptibility to torpor","volume":"581","author":"Cariou","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0016-5085(03)00896-5","article-title":"Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression","volume":"125","author":"Claudel","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1016\/j.bmcl.2010.06.084","article-title":"Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists","volume":"20","author":"Abel","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the nuclear FXR improves hyperglycemia and hyperlipidemia in diabetic mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.23408","article-title":"Bile Salt Sequestration Induces Hepatic de Novo Lipogenesis Through Farnesoid X Receptor- and Liver X Receptor\u03b1-Controlled Metabolic Pathways in Mice","volume":"51","author":"Herrema","year":"2010","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.23831","article-title":"Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism","volume":"52","author":"Brufau","year":"2010","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00125-011-2382-3","article-title":"Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: A randomised controlled study","volume":"55","author":"Beysen","year":"2012","journal-title":"Diabetologia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000174548","article-title":"Mechanism of action of bile acid sequestrants and other lipid-lowering drugs","volume":"76","author":"Shepherd","year":"1989","journal-title":"Cardiology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2362.1984.tb01129.x","article-title":"Triglyceride metabolism in human liver: Studies on hepatic phosphatidic-acid phosphatase in obese and non-obese subjects","volume":"14","author":"Angelin","year":"1984","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of Bempedoic Acid Administration with Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients with Hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/clc.4960240610","article-title":"Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia","volume":"24","author":"Davidson","year":"2001","journal-title":"Clin. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia","volume":"110","author":"Knapp","year":"2001","journal-title":"Am. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.amjmed.2020.03.056","article-title":"A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy","volume":"133","author":"Alder","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4158\/EP09146.OR","article-title":"Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy","volume":"16","author":"Rigby","year":"2010","journal-title":"Endocr. Pract."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1055\/s-0034-1383648","article-title":"Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus","volume":"46","author":"Rosenstock","year":"2014","journal-title":"Horm. Metab. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4158\/EP11218.OR","article-title":"Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: A pooled analysis from 3 clinical studies","volume":"17","author":"Bays","year":"2011","journal-title":"Endocr. Pract."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jacl.2012.05.005","article-title":"Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus","volume":"6","author":"Goldberg","year":"2012","journal-title":"J. Clin. Lipidol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jdiacomp.2017.01.011","article-title":"Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials","volume":"31","author":"Hansen","year":"2017","journal-title":"J. Diabetes Complicat."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"17887","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: A systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4158\/EP.13.1.11","article-title":"Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance","volume":"13","author":"Rivers","year":"2007","journal-title":"Endocr. Pract."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.atherosclerosis.2011.03.012","article-title":"Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes","volume":"217","author":"Bozzetto","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11745-010-3409-0","article-title":"The Effects of ezetimibe and\/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients","volume":"45","author":"Nakou","year":"2010","journal-title":"Lipids"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.clinthera.2010.04.014","article-title":"Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: A 12-week, multicenter, randomized, double-blind, controlled trial","volume":"32","author":"Huijgen","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.clinthera.2004.11.001","article-title":"Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open-label, multicenter trial","volume":"26","author":"Ballantyne","year":"2004","journal-title":"Clin. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.amjcard.2016.02.011","article-title":"A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients with Hypertriglyceridemia","volume":"117","author":"Karlson","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1185\/03007990802177150","article-title":"The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia","volume":"24","author":"Nakou","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fphar.2018.00931","article-title":"Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH","volume":"9","author":"Marschall","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"107539","DOI":"10.1016\/j.pharmthera.2020.107539","article-title":"Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges","volume":"212","author":"Li","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12072-020-10070-w","article-title":"Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders","volume":"14","author":"Karpen","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2036.2011.04675.x","article-title":"Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation\u2014A double-blind study","volume":"34","author":"Bajor","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/ajg.2011.285","article-title":"Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation","volume":"106","author":"Wong","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: Results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/bcp.13698","article-title":"Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial","volume":"84","author":"Kumagai","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/dom.12656","article-title":"Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: Double-blind randomized trials with type 2 diabetes subjects taking metformin","volume":"18","author":"Nunez","year":"2016","journal-title":"Diabetes, Obes. Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/apt.13457","article-title":"The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation","volume":"43","author":"Graffner","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","article-title":"Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis","volume":"8","author":"Wahlin","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.amjmed.2011.03.026","article-title":"Constipation and risk of cardiovascular disease among postmenopausal women","volume":"124","author":"Crawford","year":"2011","journal-title":"Am. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cpt.1222","article-title":"Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective","volume":"104","author":"Kenna","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s10038-018-0431-1","article-title":"Clinical phenotype and molecular analysis of a homozygous ABCB11 mutation responsible for progressive infantile cholestasis","volume":"63","author":"Imagawa","year":"2018","journal-title":"J. Hum. Genet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/14728222.2016.1102889","article-title":"Recent advances in the exploration of the bile salt export pump (BSEP\/ABCB11) function","volume":"20","author":"Telbisz","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"G450","DOI":"10.1152\/ajpgi.00391.2014","article-title":"The mechanism of increased biliary lipid secretion in mice with genetic inactivation of bile salt export pump","volume":"308","author":"Gooijert","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1053\/j.gastro.2011.06.062","article-title":"Hepatic overexpression of abcb11 promotes hypercholesterolemia and obesity in mice","volume":"141","author":"Henkel","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","article-title":"Bile acid transporters","volume":"50","author":"Dawson","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.22771","article-title":"High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis","volume":"49","author":"Schaap","year":"2009","journal-title":"Hepatology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"G1124","DOI":"10.1152\/ajpgi.00539.2005","article-title":"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OST\u03b1-OST\u03b2 in cholestasis in humans and rodents","volume":"290","author":"Boyer","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"G597","DOI":"10.1152\/ajpgi.00310.2017","article-title":"Organic solute transporter OST\u03b1\/\u03b2 is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury","volume":"314","author":"Malinen","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/hep.31087","article-title":"Organic Solute Transporter Alpha Deficiency: A Disorder With Cholestasis, Liver Fibrosis, and Congenital Diarrhea","volume":"71","author":"Gao","year":"2020","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.29516","article-title":"Organic solute transporter-\u03b2 (SLC51B) deficiency in two brothers with congenital diarrhea and features of cholestasis","volume":"68","author":"Sultan","year":"2018","journal-title":"Hepatology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1053\/gast.2002.33617","article-title":"Transporter-mediated bile acid uptake causes Ca2+-dependent cell death in rat pancreatic acinar cells","volume":"122","author":"Kim","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.27694","article-title":"Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice","volume":"62","author":"Slijepcevic","year":"2015","journal-title":"Hepatology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/hep.27240","article-title":"Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype","volume":"61","author":"Vaz","year":"2015","journal-title":"Hepatology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.3892\/etm.2016.3752","article-title":"Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency","volume":"12","author":"Deng","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_122","first-page":"4915","article-title":"Clinical and molecular characterization of four patients with NTCP deficiency from two unrelated families harboring the novel SLC10A1 variant c.595A>C (p.Ser199Arg)","volume":"20","author":"Li","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"15307","DOI":"10.1038\/s41598-017-15338-0","article-title":"Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP","volume":"7","author":"Donkers","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_124","first-page":"451","article-title":"Inhibition of Hepatic Bile Acid Uptake by Myrcludex B Promotes Glucagon-Like Peptide-1 Release and Reduces Obesity","volume":"10","author":"Donkers","year":"2020","journal-title":"CMGH"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.744","article-title":"The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics","volume":"103","author":"Blank","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid x receptor agonist Obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.12999","article-title":"The response of patients with bile acid diarrhoea to the farnesoid x receptor agonist obeticholic acid","volume":"41","author":"Walters","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12681","article-title":"Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers","volume":"18","author":"Pencek","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2018.06.038","article-title":"An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers","volume":"155","author":"Rudling","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"G682","DOI":"10.1152\/ajpgi.00386.2018","article-title":"Bile acid treatment and FXR agonism lower postprandial lipemia in mice","volume":"318","author":"Farr","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.bmcl.2009.04.047","article-title":"Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064","volume":"19","author":"Bass","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1002\/jps.22664","article-title":"A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys","volume":"100","author":"Chiang","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/cpdd.960","article-title":"Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers","volume":"10","author":"Wang","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Ratziu, V., Rinella, M.E., Neuschwander-Tetri, B.A., Lawitz, E., Denham, D., Kayali, Z., Sheikh, A., Kowdley, K.V., Desta, T., and Elkhashab, M. (2021). EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J. Hepatol.","DOI":"10.1016\/j.jhep.2021.10.018"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: How are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","article-title":"TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading","volume":"14","author":"Pols","year":"2011","journal-title":"Cell Metab."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.01.139","article-title":"Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1","volume":"329","author":"Katsuma","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1677\/joe.1.06546","article-title":"Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1\/M-Bar) in mice","volume":"191","author":"Maruyama","year":"2006","journal-title":"J. Endocrinol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1042\/BJ20060537","article-title":"Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation","volume":"398","author":"Vassileva","year":"2006","journal-title":"Biochem. J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2018.12.018","article-title":"Developments in bile salt based therapies: A critical overview","volume":"161","author":"Donkers","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/ng.221","article-title":"Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility","volume":"40","author":"Franke","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2009.11.046","article-title":"Genome-Wide Association Analysis in Primary Sclerosing Cholangitis","volume":"138","author":"Karlsen","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Hov, J.R., Keitel, V., Laerdahl, J.K., Spomer, L., Ellinghaus, E., Elsharawy, A., Melum, E., Boberg, K.M., Manke, T., and Balschun, T. (2010). Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012403"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpdd.34","article-title":"Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 Agonist, SB-756050, in Type 2 Diabetes","volume":"2","author":"Hodge","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1074\/jbc.M109.083899","article-title":"Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia","volume":"285","author":"Zhang","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e00390","DOI":"10.1002\/prp2.390","article-title":"Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents","volume":"6","author":"Shinozawa","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1194\/jlr.M070888","article-title":"Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters","volume":"58","author":"Dong","year":"2017","journal-title":"J. Lipid Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"E716","DOI":"10.1152\/ajpendo.00355.2005","article-title":"Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters","volume":"290","author":"Bilz","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/1\/4\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:50:18Z","timestamp":1760169018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/1\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["jcm11010004"],"URL":"https:\/\/doi.org\/10.3390\/jcm11010004","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}